The global intracranial pressure monitoring devices market size was valued at USD 1.56 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2032.
Report Scope of The Intracranial Pressure Monitoring Devices Market:
|Market Size In 2022||USD 1.56 Billion|
|Revenue Forecast By 2032||USD 3.31 Billion|
|Growth Rate From 2023 to 2032||7.8%|
|Segments Covered||Technique, Application|
|Market Analysis (Terms Used)||Revenue In USD Million/Billion And CAGR From 2023 To 2032|
|Regional Scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Key Companies Profiled||Medtronic; Integra Lifesciences; Raumedic AG; Sophysa; Spiegelberg GmbH; Natus Medical; Gaeltec Devices; Neural Analytics|
The growth of the market is attributed to the increasing prevalence of neurological disorders, the rapidly growing geriatric population in Asia Pacific, especially in countries such as Japan, India, and China, and rapid technological improvements. The COVID-19 pandemic is expected to have a short-term and moderate impact on the intracranial pressure (ICP) monitoring devices market. The COVID-19 pandemic has mostly provided an opportunity to minimize ICU utilization and accelerate patient release without increasing complications, readmissions, or reoperations.
In addition, stricter patient education, recovery room evaluation for non-ICU hospitalization, faster mobilization, post-discharge communication, increased adoption of minimally invasive surgeries, TIVA anesthesia, and early post imaging are expected to contribute to market growth. Hence, the existing invasive method is the primary technique utilized for intracranial monitoring. However, the development and usage of non-invasive methods for intracranial pressure monitoring are estimated to provide lucrative opportunities to key market players. For instance, according to ClinicalTrials.gov, as updated in April 2021, a clinical trial studying ‘intracranial pressure monitoring device performed in non-invasive method’ developed by Brain4Care is currently ongoing. This technology allows non-invasive assessment of the patient's status, which decreases a major risk of adverse effects while also lowering the expense of monitoring, which is expected to boost the growth of the market for intracranial pressure monitoring devices in near future.
In addition, a non-invasive intracranial pressure monitor may also be a significant research tool for studying pathophysiology and evaluating the efficiency of intracranial hypertension therapy. There might be prospects for space medical applications or studies on intracranial pressure responses at high altitudes. Hence, owing to the aforementioned factors, non-invasive intracranial pressure monitoring is expected to contribute to market growth, providing profitable opportunities for key players post COVID-19. A high-impact primary driver of the market for intracranial pressure monitoring devices is the growing need for minimally invasive surgical techniques due to improved patient outcomes.
In addition, the currently used ICP measurement requires puncturing a hole in the skull and inserting a catheter into the ventricular space for draining cerebrospinal fluid. There is a scarcity of experienced specialists, hence invasive procedures are not possible in a variety of situations, including emergencies. Thus, non-invasive methods such as transcranial Doppler ultrasonography, MRI/CT, and optic nerve sheath diameter are considered promising techniques to overcome these problems. For instance, Vittamed 205 developed by Vittamed Corporation, and Cerepress developed by Third Eye Diagnostics, are designed to measure and monitor ICP noninvasively via the eye.
In December 2022, Natus Medical Incorporated reached an agreement to acquire Micromed Holding SAS. Micromed and Natus work together to provide their customers with better neuromonitoring and neurodiagnostic solutions.
Similarly, HS-1000M Monitor by HeadSense Medical Ltd. and MMS-14 developed by Marchbanks Measurement Systems, use acoustic sound to measure and monitor ICP noninvasively through the ears. They are intended to be used in patients affected with stroke, traumatic brain injury/concussions, hydrocephalus, neurologic conditions, and other pathologies that may lead to intracranial hyper- and hypotension. Various benefits associated with these procedures, such as smaller incisions, faster recovery time, lower trauma, and low risk of complications, are contributing to market growth. Moreover, the increasing prevalence of neurological disorders, such as brain infection, hydrocephalus, aneurysm, intracranial tumors, and meningitis, and the growing incidence of trauma events due to road accidents, sports injuries, and falls worldwide are anticipated to drive the market for intracranial pressure monitoring devices.
For instance, according to the WHO, around 1.3 million people died globally in 2021 due to road accidents. In addition, between 20 and 50 million more people suffer non-fatal injuries, with many incurring a disability because of their injury. Road accidents are more common in middle- or low-income countries. Similarly, as per the same report, during 2009-2018, an estimated 596,972 ED visits for bicycle-related TBIs occurred in the U.S. These injuries or traumas result in elevated ICP, which in turn is expected to increase the demand for ICP monitoring devices, thereby positively influencing the growth of the market for intracranial pressure monitoring devices. In addition, the development of advanced devices, such as surgical microscopes, neurosurgery devices, ophthalmic surgical devices, and surgical robots, has led to a reduction in direct human interference in surgical procedures.
Technologically advanced ICP monitoring devices are reducing drawbacks of earlier invasive devices, such as a spontaneous shift in baseline pressure and leveling and de-bubbling associated with fluid-filled systems. For instance, medical robotics has been witnessing a paradigm shift over the years due to technological advancements in the area of 3D imaging. High-definition microscope cameras, data recorders, data analytic systems, motion sensors, remote navigation systems, and robotic-controlled catheters and transducers are some of the recent innovations. The aim of technological advancements is to find new applications for existing platforms as well as create disruptive technologies that drive the market for intracranial pressure monitoring devices.
The industry is witnessing a growing trend of robotic companies collaborating with third-party vendors to develop new applications of technology platforms. Furthermore, there is a trend of consolidation of technologies by big players in niche areas through mergers and acquisitions which is also increasing market growth. The U.S dominated the market with the highest share. This can be attributed to the increasing incidence of Traumatic Brain Injury (TBI) and migraine in the U.S. On the other hand, companies are also working on a range of strategic sourcing and diversity programs. For instance, in July 2019, Integra LifeSciences acquired Arkis BioSciences, Inc. This acquisition was expected to help Integra LifeSciences strengthen its product portfolio in neurocritical care and advanced catheter technology. Both companies will work on a range of areas, including co-marketing opportunities, product development, sustainable manufacturing, strategic sourcing, and diversity programs, which are expected to boost market growth soon.
Intracranial Pressure Monitoring Devices Market Report Segmentation: